Briumvi’s Phase 3 trial of an at-home injection has completed enrollment, testing an under-the-skin version against IV ...

Please provide your email address to receive an email when new articles are posted on . Adults either continued to receive ublituximab or switched from teriflunomide to ublituximab in this 3-year open ...

Phase 3 trial evaluated two subcutaneous BRIUMVI dosing regimens; administration every 2 months or every 3 monthsTop-line data expected year-end ...

A woman in her 50s with genetically confirmed Huntington’s disease presented with right-sided arm sensory symptoms that ...

In the above studies in PPMS and RMS, GA Depot showed EDSS stabilization, irrespective of baseline EDSS scores. These EDSS findings suggest GA Depot's potential in slowing disability progression, ...

Insights from AAN 2026, including anticipated presentations, key takeaways, and how emerging research in RRMS may affect patient care.

Dr Chu-Yueh Guo prepares to discover how the latest diagnostic criteria and breakthrough treatments are reshaping the landscape of RRMS.

FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

- FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

(BPT) - Visit MSInspiration.com for a chance to win a day of inspiration! At first glance, Marci Viland and Chris Wright don’t have very much in common. Their paths have never crossed, they live in ...